
Helena J Tutill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7170509/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Low Prevalence of Conjunctival Infection with Chlamydia trachomatis in a Treatment-NaÃ ⁻ ve Trachoma-Endemic Region of the Solomon Islands. PLoS Neglected Tropical Diseases, 2016, 10, e0004863.	3.0	42
2	The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors. Molecular and Cellular Endocrinology, 2009, 301, 259-265.	3.2	26
3	Novel, potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Molecular and Cellular Endocrinology, 2006, 248, 204-207.	3.2	23
4	STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. Endocrine-Related Cancer, 2013, 20, 53-64.	3.1	17
5	Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase Type 3. Molecular and Cellular Endocrinology, 2009, 301, 251-258.	3.2	16
6	NIX-mediated mitophagy regulate metabolic reprogramming in phagocytic cells during mycobacterial infection. Tuberculosis, 2021, 126, 102046.	1.9	16
7	Kallikrein-Mediated Cytokeratin 10 Degradation Is Required for Varicella Zoster Virus Propagation in Skin. Journal of Investigative Dermatology, 2020, 140, 774-784.e11.	0.7	13
8	Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 3. Molecules, 2021, 26, 7166.	3.8	1